Karen McCoy

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.3K citations · Full text

Mendelian Disorder, Genetics, Ivacaftor Combination Regimen +2

Longitudinal Assessment of<i>Pseudomonas aeruginosa</i>in Young Children with Cystic Fibrosis

Jane L. Burns, Ronald L. Gibson, Sharon McNamara et al. · The Journal of Infectious Diseases · 2001 · 556 citations · Full text

Antibiotics, Medicine, Pediatrics +11

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 493 citations · Full text

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*

Margaret Rosenfeld, Ronald L. Gibson, Sharon McNamara et al. · Pediatric Pulmonology · 2001 · 392 citations